Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 5/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LCAT | P04180 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749116 | 0.89 | ACACB (0.37) | ACACBARHRH3FPR2PROKR1 | |
| SCHEMBL30748874 | 0.89 | CHRM4 (0.45) | ACACBARHRH3FPR2PROKR1 | |
| SCHEMBL30748857 | 0.85 | HRH3 (0.39) | HRH3KCNH2 | |
| SCHEMBL31691230 | 0.83 | ACACB (0.33) | ACACBARHRH3LCAT | |
| SCHEMBL30748799 | 0.80 | ACACB (0.34) | ACACBARHRH3FPR2PROKR1 | |
| SCHEMBL30748804 | 0.80 | ACACB (0.38) | ACACBARHRH3KCNH2LCAT | |
| SCHEMBL30749042 | 0.79 | ACACB (0.38) | ACACBARHRH3KCNH2LCAT | |
| SCHEMBL30748806 | 0.79 | AR (0.38) | ACACBARHRH3FPR2PROKR1 | |
| SCHEMBL30748989 | 0.78 | ACACB (0.39) | ACACBARHRH3LCATBTK | |
| SCHEMBL30748958 | 0.78 | AR (0.38) | ACACBARHRH3FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | ACACB 1127/4885AR 57/4885HRH3 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.